Current Problems in Pediatric and Adolescent Health Care
Volume 37, Issue 2 , Pages 50-72 , February 2007

Current Concepts in Normal and Abnormal Puberty

References 

  1. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291–303
  2. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45:13–23
  3. Mitsushima D, Hei DL, Terasawa E. γ-Aminobutyric acid is an inhibitory neurotransmitter restricting the release of luteinizing hormone-releasing hormone before the onset of puberty. Proc Natl Acad Sci USA. 1994;91:395–399
  4. Garcia-Mayor RV, Andrade MA, Rios M, Lage M, Dieguez C, Casanueva FF. Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-gonadal hormones, and pubertal stage. J Clin Endocrinol Metab. 1997;82:2849–2855
  5. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA. 2003;100:10972–10976
  6. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349:1614–1627
  7. Tena-Sempere M. The roles of kisspeptins and G protein-coupled receptor-54 in pubertal development. Curr Opin Pediatr. 2006;18:442–447
  8. Lee PA. Normal ages of pubertal events among American males and females. J Adolesc Health Care. 1980;1:26–29
  9. Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997;99:505–512
  10. Herman-Giddens ME, Wang L, Koch G. Secondary sexual characteristics in boys: estimates from the national health and nutrition examination survey III, 1988-1994. Arch Pediatr Adolesc Med. 2001;155:1022–1028
  11. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment (Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society). Pediatrics. 1999;104:936–941
  12. Rosenfield RL, Bachrach LK, Chernausek SD, Gertner JM, Gottschalk M, Hardin DS, et al. Current age of onset of puberty. Pediatrics. 2000;106:622–623
  13. Kaplowitz PB, Slora EJ, Wasserman RC, Pedlow SE, Herman-Giddens ME. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics. 2001;108:347–353
  14. Midyett LK, Moore WV, Jacobson JD. Are pubertal changes in girls before age 8 benign?. Pediatrics. 2003;111:47–51
  15. Wyshak G, Frisch RE. Evidence for a secular trend in age of menarche. N Engl J Med. 1982;306:1033–1035
  16. Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr. 2005;147:753–760
  17. Van Winter JT, Noller KL, Zimmerman D, Melton LJ. Natural history of premature thelarche in Olmsted County, Minnesota, 1940 to 1984. J Pediatr. 1990;116:278–280
  18. Volta C, Bernasconi S, Cisternino M, Buzi F, Ferzetti A, Street ME, et al. Isolated premature thelarche and thelarche variant: clinical and auxological follow-up of 119 girls. J Endocrinol Invest. 1998;21:180–183
  19. Salardi S, Cacciari E, Mainetti B, Mazzanti L, Pirazzoli P. Outcome of premature thelarche: relation to puberty and final height. Arch Dis Child. 1998;79:173–174
  20. Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB. Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1988;67:474–479
  21. Auchus RJ, Rainey WE. Adrenarche—physiology, biochemistry and human disease. Clin Endocrinol (Oxf). 2004;60:288–296
  22. Saenger P, Reiter EO. Premature adrenarche: a normal variant of puberty?. J Clin Endocrinol Metab. 1992;74:236–238
  23. Kaplan SL, Grumbach MM. Clinical review 14: pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab. 1990;71:785–789
  24. Ibanez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche—normal variant or forerunner of adult disease?. Endocr Rev. 2000;21:671–696
  25. Ibanez L, Potau N, Chacon P, Pascual C, Carrascosa A. Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia. 1998;41:1057–1063
  26. Ibanez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993;76:1599–1603
  27. Ibanez L, Potau N, Marcos MV, De Zegher F. Adrenal hyperandrogenism in adolescent girls with a history of low birthweight and precocious pubarche. Clin Endocrinol (Oxf). 2000;53:523–527
  28. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. Arch Dis Child. 1994;70:116–118
  29. Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, et al. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics. 1996;97:517–519
  30. Ibanez L, Potau N, Zampolli M, Virdis R, Gussinye M, Carrascosa A, et al. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test. J Clin Endocrinol Metab. 1994;78:30–35
  31. Lee PA. Central precocious puberty (An overview of diagnosis, treatment, and outcome). Endocrinol Metab Clin North Am. 1999;28:901–918xi.
  32. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995;127:47–52
  33. Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, Foster C, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986;108:47–54
  34. Chalumeau M, Chemaitilly W, Trivin C, Adan L, Breart G, Brauner R. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics. 2002;109:61–67
  35. Ng SM, Kumar Y, Cody D, Smith CS, Didi M. Cranial MRI scans are indicated in all girls with central precocious puberty. Arch Dis Child. 2003;88:414–418
  36. Maixner W. Hypothalamic hamartomas-clinical, neuropathological and surgical aspects. Childs Nerv Syst. 2006;22:867–873
  37. Jung H, Neumaier Probst E, Hauffa BP, Partsch CJ, Dammann O. Association of morphological characteristics with precocious puberty and/or gelastic seizures in hypothalamic hamartoma. J Clin Endocrinol Metab. 2003;88:4590–4595
  38. Judge DM, Kulin HE, Page R, Santen R, Trapukdi S. Hypothalamic hamartoma: a source of luteinizing-hormone-releasing factor in precocious puberty. N Engl J Med. 1977;296:7–10
  39. Jung H, Carmel P, Schwartz MS, Witkin JW, Bentele KH, Westphal M, et al. Some hypothalamic hamartomas contain transforming growth factor alpha, a puberty-inducing growth factor, but not luteinizing hormone-releasing hormone neurons. J Clin Endocrinol Metab. 1999;84:4695–4701
  40. Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr. 1995;126:364–367
  41. Cnossen MH, Stam EN, Cooiman LC, Simonsz HJ, Stroink H, Oranje AP, et al. Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics. 1997;100:667–670
  42. Virdis R, Sigorini M, Laiolo A, Lorenzetti E, Street ME, Villani AR, et al. Neurofibromatosis type 1 and precocious puberty. J Pediatr Endocrinol Metab. 2000;13(Suppl 1):841–844
  43. Geffner ME, Connelly K, Hunold JJ, Landt K, Eugster EA, Hoffman A, et al. In: Growth hormone (GH) treatment in children with neurofibromatosis (NF): efficacy data from the National Cooperative Growth Study (NCGS). 2006;p. 2–672The Endocrine Society’s 88th Annual Meeting [abstract]. Boston
  44. Faggiano M, Criscuolo T, Perrone L, Quarto C, Sinisi AA. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol (Copenh). 1983;102:167–172
  45. Ambrosi B, Bassetti M, Ferrario R, Medri G, Giannattasio G, Faglia G. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: hormonal and immunocytochemical studies. Acta Endocrinol (Copenh). 1990;122:569–576
  46. Klein KO. Precocious puberty: who has it? Who should be treated?. J Clin Endocrinol Metab. 1999;84:411–414
  47. Rosenfield RL. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr. 1994;124:989–991
  48. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd Edition. Stanford (CA): Stanford University Press; 1959;
  49. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40:423–441
  50. Kreiter M, Burstein S, Rosenfield RL, Moll GW, Cara JF, Yousefzadeh DK, et al. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr. 1990;117:364–370
  51. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab. 1999;84:415–423
  52. Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?. J Pediatr. 2000;137:819–825
  53. Sonis WA, Comite F, Blue J, Pescovitz OH, Rahn CW, Hench KD, et al. Behavior problems and social competence in girls with true precocious puberty. J Pediatr. 1985;106:156–160
  54. Ehrhardt AA, Meyer-Bahlburg HF, Bell JJ, Cohen SF, Healey JM, Stiel R, et al. Idiopathic precocious puberty in girls: psychiatric follow-up in adolescence. J Am Acad Child Psychiatry. 1984;23:23–33
  55. Cutler GB, Hoffman AR, Swerdloff RS, Santen RJ, Meldrum DR, Comite F. NIH conference (Therapeutic applications of luteinizing-hormone-releasing hormone and its analogs). Ann Intern Med. 1985;102:643–657
  56. Mahachoklertwattana P, Kaplan SL, Grumbach MM. The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: natural history. J Clin Endocrinol Metab. 1993;77:118–124
  57. Pescovitz OH, Comite F, Cassorla F, Dwyer AJ, Poth MA, Sperling MA, et al. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab. 1984;58:857–861
  58. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab. 2002;87:4111–4116
  59. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006;91:1862–1867
  60. Foster CM. Editorial: does lupron dosage make a difference in outcome when treating children with precocious puberty?. J Clin Endocrinol Metab. 2006;91:1667–1668
  61. Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics. 2005;116:e798–e802
  62. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics. 2002;109:E30
  63. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab. 2004;89:4338–4342
  64. Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab. 1999;84:44–49
  65. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function (The TAP-144-SR Japanese Study Group on Central Precocious Puberty). J Clin Endocrinol Metab. 2005;90:1371–1376
  66. Jay N, Mansfield MJ, Blizzard RM, Crowley WF, Schoenfeld D, Rhubin L, et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 1992;75:890–894
  67. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr. 1998;157:363–367
  68. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999;84:4583–4590
  69. Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab. 2003;88:1096–1101
  70. Roth C. Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Exp Opin Investig Drugs. 2002;11:1253–1259
  71. Schultze-Mosgau A, Griesinger G, Altgassen C, von Otte S, Hornung D, Diedrich K. New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs. 2005;14:1085–1097
  72. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21:245–291
  73. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr. 2001;138:26–32
  74. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001;22:675–705
  75. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325:1688–1695
  76. Lumbroso S, Paris F, Sultan C. Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome—a European Collaborative Study. J Clin Endocrinol Metab. 2004;89:2107–2113
  77. Eugster EA, Pescovitz OH. Precocious puberty. In:  DeGroot JL,  Jameson JL editor. Endocrinology. 5th Edition.. Philadelphia (PA): Elsevier; 2006;p. 2831–2846
  78. Feuillan PP, Jones J, Cutler GB. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab. 1993;77:647–651
  79. Nunez SB, Calis K, Cutler GB, Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab. 2003;88:5730–5733
  80. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J Pediatr Endocrinol Metab. 1999;12:681–686
  81. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr. 2003;143:60–66
  82. Sawathiparnich P, Osuwanaratana P, Santiprabhob J, Likitmaskul S. Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review. J Pediatr Endocrinol Metab. 2006;19:81–86
  83. Gunther DF, Calikoglu AS, Underwood LE. The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatr Res. 1999;46:269–273
  84. Shenker A, Laue L, Kosugi S, Merendino JJ, Minegishi T, Cutler GB. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature. 1993;365:652–654
  85. Leschek EW. Familial male-limited precocious puberty. Endocrinologist. 2004;14:148–151
  86. Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med. 1985;312:1023–1028
  87. Soriano-Guillen L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab. 2005;90:147–151
  88. Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 1989;320:496–502
  89. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab. 1999;84:175–178
  90. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr. 2006;149:416–420
  91. Bhansali A, Kashyap A, Lodha S, Kotwal N, Ganapathi B, Mittal BR, et al. Isosexual precocity: uncommon presentation of a common disorder. Postgrad Med J. 2000;76:177–178
  92. Phupong V, Aribarg A. Vaginal bleeding in a young girl due to primary hypothyroidism. Arch Gynecol Obstet. 2003;268:217–218
  93. Anasti JN, Flack MR, Froehlich J, Nelson LM, Nisula BC. A potential novel mechanism for precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab. 1995;80:276–279
  94. Nebesio TD, Pescovitz OH. Historical perspectives: endocrine disruptors and the timing of puberty. Endocrinologist. 2005;15:44–48
  95. Nebesio TD, Pescovitz OH. The role of endocrine disruptors in pubertal development. In: Walvoord EC, Pescovitz OH, editors. When puberty is precocious: scientific and clinical aspects. Totowa (NJ): Humana Press, Inc.; in press.
  96. Comas AP. Precocious sexual development in Puerto Rico. Lancet. 1982;1:1299–1300
  97. Saenz de Rodriguez CA, Bongiovanni AM, Conde de Borrego L. An epidemic of precocious development in Puerto Rican children. J Pediatr. 1985;107:393–396
  98. Shea KM. Pediatric exposure and potential toxicity of phthalate plasticizers. Pediatrics. 2003;111:1467–1474
  99. Colon I, Caro D, Bourdony CJ, Rosario O. Identification of phthalate esters in the serum of young Puerto Rican girls with premature breast development. Environ Health Perspect. 2000;108:895–900
  100. Krstevska-Konstantinova M, Charlier C, Craen M, Du Caju M, Heinrichs C, de Beaufort C, et al. Sexual precocity after immigration from developing countries to Belgium: evidence of previous exposure to organochlorine pesticides. Hum Reprod. 2001;16:1020–1026
  101. Boneh A, Landau H, Friedlander N. Age and seasonal factors in the incidence of premature sexual development in girls in the Jerusalem area. Clin Invest Med. 1989;12:172–174
  102. Felner EI, White PC. Prepubertal gynecomastia: indirect exposure to estrogen cream. Pediatrics. 2000;105:E55
  103. Henley D, Bloch C, Korach K. Components of health care products associated with male prepubertal gynecomastia possess estrogenic and antiandrogenic activities. The Endocrine Society’s 88th Annual Meeting [abstract]. Boston 2006;1-162.
  104. Zimmerman PA, Francis GL, Poth M. Hormone-containing cosmetics may cause signs of early sexual development. Mil Med. 1995;160:628–630
  105. Tiwary CM. Premature sexual development in children following the use of estrogen- or placenta-containing hair products. Clin Pediatr (Phila). 1998;37:733–739
  106. Kunz GJ, Klein KO, Clemons RD, Gottschalk ME, Jones KL. Virilization of young children after topical androgen use by their parents. Pediatrics. 2004;114:282–284
  107. Patil KK, Ransley PG, McCullagh M, Malone M, Spitz L. Functioning adrenocortical neoplasms in children. BJU Int. 2002;89:562–565
  108. Dufau ML. The luteinizing hormone receptor. Annu Rev Physiol. 1998;60:461–496
  109. Alikasifoglu A, Gonc EN, Akcoren Z, Kale G, Ciftci AO, Senocak ME, et al. Feminizing Sertoli cell tumor associated with Peutz-Jeghers syndrome. J Pediatr Endocrinol Metab. 2002;15:449–452
  110. Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab. 1998;83:1348–1357
  111. Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med. 2003;348:1855–1865
  112. Snoga JR, Morgan RL, Lundberg GD. Idiopathic prepuberal hypertrophy of the male breast (Histochemical evaluation and relation to gynecomastia and other disorders of the breast). Am J Clin Pathol. 1965;44:458–463
  113. August GP, Chandra R, Hung W. Prepubertal male gynecomastia. J Pediatr. 1972;80:259–263
  114. Latorre H, Kenny FM. Idiopathic gynecomastia in seven preadolescent boys (Elevation of urinary estrogen excretion in two cases). Am J Dis Child. 1973;126:771–773
  115. Einav-Bachar R, Phillip M, Aurbach-Klipper Y, Lazar L. Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol (Oxf). 2004;61:55–60
  116. Nebesio TD, Davis MM, Billmire DF, Eugster EA. Giant cell fibroblastoma masquerading as prepubertal gynecomastia. Clin Pediatr (Phila). 2005;44:355–357
  117. Layfield LJ, Gopez EV. Fine-needle aspiration cytology of giant cell fibroblastoma: case report and review of the literature. Diagn Cytopathol. 2002;26:398–403
  118. Diamond FB, Shulman DI, Root AW. Scrotal hair in infancy. J Pediatr. 1989;114:999–1001
  119. Francis JS, Ruvalcaba RH. Scrotal hair growth in infancy. Pediatr Dermatol. 1993;10:389–390
  120. Papadimitriou A, Beri D, Nicolaidou P. Isolated scrotal hair in infancy. J Pediatr. 2006;148(5):690–691
  121. Nebesio TD, Eugster EA. Pubic hair of infancy: endocrinopathy or enigma?. Pediatrics. 2006;117:951–954
  122. Silverman SH, Migeon C, Rosemberg E, Wilkins L. Precocious growth of sexual hair without other secondary sexual development; premature pubarche, a constitutional variation of adolescence. Pediatrics. 1952;10:426–432
  123. Adams DM, Young PC, Copeland KC. Pubic hair in infancy. Am J Dis Child. 1992;146:149–151
  124. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab. 2004;89:3644–3650
  125. Fishman A, Paldi E. Vaginal bleeding in premenarchal girls: a review. Obstet Gynecol Surv. 1991;46:457–460
  126. Hill NC, Oppenheimer LW, Morton KE. The aetiology of vaginal bleeding in children (A 20-year review). Br J Obstet Gynaecol. 1989;96:467–470
  127. Heller ME, Dewhurst J, Grant DB. Premature menarche without other evidence of precocious puberty. Arch Dis Child. 1979;54:472–475
  128. Murram D, Dewhurst J, Grant DB. Premature menarche: a follow-up study. Arch Dis Child. 1983;58:142–143
  129. Blanco-Garcia M, Evain-Brion D, Roger M, Job JC. Isolated menses in prepubertal girls. Pediatrics. 1985;76:43–47
  130. Sedlmeyer IL, Palmert MR. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab. 2002;87:1613–1620
  131. Palmert MR, Boepple PA. Variation in the timing of puberty: clinical spectrum and genetic investigation. J Clin Endocrinol Metab. 2001;86:2364–2368
  132. Krupa B, Miazgowski T. Bone mineral density and markers of bone turnover in boys with constitutional delay of growth and puberty. J Clin Endocrinol Metab. 2005;90:2828–2830
  133. Butenandt O, Bechtold S, Meidert A. Final height in patients with constitutional delay of growth and development from tall statured families. J Pediatr Endocrinol Metab. 2005;18:165–169
  134. Kalantaridou SN, Chrousos GP. Clinical review 148: monogenic disorders of puberty. J Clin Endocrinol Metab. 2002;87:2481–2494
  135. Cogan JD, Wu W, Phillips JA, Arnhold IJ, Agapito A, Fofanova OV, et al. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab. 1998;83:3346–3349
  136. Reynaud R, Gueydan M, Saveanu A, Vallette-Kasic S, Enjalbert A, Brue T, et al. Genetic screening of combined pituitary hormone deficiency: experience in 195 patients. J Clin Endocrinol Metab. 2006;91:3329–3336
  137. Seminara SB, Hayes FJ, Crowley WF. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): pathophysiological and genetic considerations. Endocr Rev. 1998;19:521–539
  138. Vogl TJ, Stemmler J, Heye B, Schopohl J, Danek A, Bergman C, et al. Kallman syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging. Radiology. 1994;191:53–57
  139. Dode C, Levilliers J, Dupont JM, De Paepe A, Le Du N, Soussi-Yanicostas N, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet. 2003;33:463–465
  140. Lin L, Gu WX, Ozisik G, To WS, Owen CJ, Jameson JL, et al. Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years’ experience. J Clin Endocrinol Metab. 2006;91:3048–3054
  141. Lin L, Achermann JC. Inherited adrenal hypoplasia: not just for kids!. Clin Endocrinol (Oxf). 2004;60:529–537
  142. Beier DR, Dluhy RG. Bench and bedside—the G protein-coupled receptor GPR54 and puberty. N Engl J Med. 2003;349:1589–1592
  143. Traggiai C, Stanhope R. Delayed puberty. Best Pract Res Clin Endocrinol Metab. 2002;16:139–151
  144. Eiholzer U, l’Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, et al. Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart-Willi syndrome. J Clin Endocrinol Metab. 2006;91:892–898
  145. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab. 2001;86:3061–3069
  146. Sybert VP, McCauley E. Turner’s syndrome. N Engl J Med. 2004;351:1227–1238
  147. Gottlieb B, Pinsky L, Beitel LK, Trifiro M. Androgen insensitivity. Am J Med Genet. 1999;89:210–217
  148. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995;16:271–321
  149. MacLaughlin DT, Donahoe PK. Sex determination and differentiation. N Engl J Med. 2004;350:367–378
  150. Bonte A, Schroder W, Denamur E, Querfeld U. Absent pubertal development in a child with chronic renal failure: the case of Frasier syndrome. Nephrol Dial Transplant. 2000;15:1688–1690
  151. Nishi Y, Hamamoto K, Kajiyama M, Kawamura I. The Perrault syndrome: clinical report and review. Am J Med Genet. 1988;31:623–629
  152. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet. 1999;22:125–126
  153. Holland C. 47, XXX in an adolescent with premature ovarian failure and autoimmune disease. J Pediatr Adolesc Gynecol. 2000;13:93
  154. Schlessinger D, Herrera L, Crisponi L, Mumm S, Percesepe A, Pellegrini M, et al. Genes and translocations involved in POF. Am J Med Genet. 2002;111:328–333
  155. Smyth CM, Bremner WJ. Klinefelter syndrome. Arch Intern Med. 1998;158:1309–1314
  156. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter’s syndrome. Lancet. 2004;364:273–283
  157. Salbenblatt JA, Bender BG, Puck MH, Robinson A, Faiman C, Winter JS. Pituitary-gonadal function in Klinefelter syndrome before and during puberty. Pediatr Res. 1985;19:82–86
  158. Aksglaede L, Wikstrom AM, Rajpert-De Meyts E, Dunkel L, Skakkebaek NE, Juul A. Natural history of seminiferous tubule degeneration in Klinefelter syndrome. Hum Reprod Update. 2006;12:39–48
  159. Rose SR. Endocrinopathies in childhood cancer survivors. Endocrinologist. 2003;13:488–495
  160. Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev. 1998;19:144–172
  161. Bakker B, Massa GG, Oostdijk W, Van Weel-Sipman MH, Vossen JM, Wit JM. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur J Pediatr. 2000;159:31–37
  162. Meacham L. Endocrine late effects of childhood cancer therapy. Curr Probl Pediatr Adolesc Health Care. 2003;33:217–242
  163. Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med. 1981;304:994–998
  164. Aaltonen J, Bjorses P, Perheentupa J, Horelli-Kuitunen N, Palotie A, Peltonen L, et al. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997;17:399–403
  165. Betterle C, Greggio NA, Volpato M. Clinical review 93: autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1998;83:1049–1055
  166. Miller WL. Disorders of androgen biosynthesis. Semin Reprod Med. 2002;20:205–216
  167. Lazala C, Saenger P. Pubertal gynecomastia. J Pediatr Endocrinol Metab. 2002;15:553–560
  168. Braunstein GD. Gynecomastia. N Engl J Med. 1993;328:490–495
  169. Nydick M, Butos J, Dale J, Rawson R. Gynecomastia in adolescent boys. JAMA. 1961;178:449–454
  170. Ismail AA, Barth JH. Endocrinology of gynaecomastia. Ann Clin Biochem. 2001;38:596–607
  171. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:4428–4433
  172. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145:71–76
  173. Doughty JC, Wilson CR. Tamoxifen is unproved for gynaecomastia. BMJ. 2003;327:1050
  174. Malozowski S. Treatment of adolescents with gynecomastia. J Pediatr. 2005;146(4):576
  175. Pearlman G, Carlson HE. Gynecomastia: an update. Endocrinologist. 2006;16:109–115
  176. Kiess W, Conway G, Ritzen M, Rosenfield R, Bernasconi S, Juul A, et al. Induction of puberty in the hypogonadal girl—practices and attitudes of pediatric endocrinologists in Europe. Horm Res. 2002;57:66–71
  177. Drobac S, Rubin K, Rogol AD, Rosenfield RL. A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab. 2006;19:55–64
  178. Ross JL, Cassorla FG, Skerda MC, Valk IM, Loriaux DL, Cutler GB. A preliminary study of the effect of estrogen dose on growth in Turner’s syndrome. N Engl J Med. 1983;309:1104–1106
  179. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25:693–721
  180. Chernausek SD, Attie KM, Cara JF, Rosenfeld RG, Frane J. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height (Genentech, Inc., Collaborative Study Group). J Clin Endocrinol Metab. 2000;85:2439–2445
  181. Carel JC, Elie C, Ecosse E, Tauber M, Leger J, Cabrol S, et al. Self-esteem and social adjustment in young women with Turner syndrome—influence of pubertal management and sexuality: population-based cohort study. J Clin Endocrinol Metab. 2006;91:2972–2979
  182. Rosenfield RL, Perovic N, Devine N, Mauras N, Moshang T, Root AW, et al. Optimizing estrogen replacement treatment in Turner syndrome. Pediatrics. 1998;102:486–488
  183. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab. 2005;90:6424–6430
  184. MacGillivray MH. Induction of puberty in hypogonadal children. J Pediatr Endocrinol Metab. 2004;17(Suppl 4):1277–1287
  185. Donaldson MD, Gault EJ, Tan KW, Dunger DB. Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child. 2006;91:513–520
  186. Paterson WF, Hollman AS, Donaldson MD. Poor uterine development in Turner syndrome with oral oestrogen therapy. Clin Endocrinol (Oxf). 2002;56:359–365
  187. Snajderova M, Mardesic T, Lebl J, Gerzova H, Teslik L, Zapletalova J. The uterine length in women with Turner syndrome reflects the postmenarcheal daily estrogen dose. Horm Res. 2003;60:198–204
  188. Burkman RT. The transdermal contraceptive system. Am J Obstet Gynecol. 2004;190(Suppl 4):S49–S53
  189. New warning on birth control patch. FDA Consum. 2006;40:4
  190. Rogol AD. New facets of androgen replacement therapy during childhood and adolescence. Expert Opin Pharmacother. 2005;6:1319–1336

PII: S1538-5442(06)00110-6

doi: 10.1016/j.cppeds.2006.10.005

Current Problems in Pediatric and Adolescent Health Care
Volume 37, Issue 2 , Pages 50-72 , February 2007

Article Tools

* Image Usage & Resolution